The use of high-impact technologies, including innovative medicines, has been identified as one of the greatest challenges facing health services in .. Read more the European Union. We are assisting with new therapies and medicines, the result of which is the cure of hitherto incurable diseases, with what this means in health results and in the reduction of suffering and medical and healthcare expenses for life. For this reason, we do not want to limit the scope of the debate at this meeting to drugs with high economic impact, which too, but rather we are going to focus rather on those innovative drugs that, being cost, have a high impact on health. During the debate, we will comment on the new Information System to determine the Therapeutic Value in Real Clinical Practice of Medicines of High Health and Economic Impact in the SNS (VALTERMED) as well as the Advanced Therapies Approach Plan of the SNS approved in 2018. We will also talk about the expected arrival of new innovative drugs that increasingly refer to more personalized targets and therapies (precision) as well as the financing policies of these therapies and drugs and how to measure their health benefits, in cost savings and economic and social productivity. To talk about these issues we have met with a sample of the different agents involved in the evaluation, approval, financing, prescription and authorization of these drugs at all levels (state, regional and hospital) in the National Health System.
- Share your Experience